KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Operating Expenses: 2018-2024

Historic Operating Expenses for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $323.4 million.

  • Castle Biosciences' Operating Expenses rose 11.33% to $89.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $378.5 million, marking a year-over-year increase of 20.95%. This contributed to the annual value of $323.4 million for FY2024, which is 12.38% up from last year.
  • According to the latest figures from FY2024, Castle Biosciences' Operating Expenses is $323.4 million, which was up 12.38% from $287.8 million recorded in FY2023.
  • Castle Biosciences' Operating Expenses' 5-year high stood at $323.4 million during FY2024, with a 5-year trough of $69.2 million in FY2020.
  • In the last 3 years, Castle Biosciences' Operating Expenses had a median value of $287.8 million in 2023 and averaged $273.7 million.
  • Data for Castle Biosciences' Operating Expenses shows a peak YoY spiked of 93.90% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Castle Biosciences' Operating Expenses stood at $69.2 million in 2020, then skyrocketed by 93.90% to $134.2 million in 2021, then surged by 56.45% to $209.9 million in 2022, then spiked by 37.10% to $287.8 million in 2023, then rose by 12.38% to $323.4 million in 2024.